Bond.az White LogoBond.az Black Logo

Barclays Reiterates Overweight on Nvidia with $275 Target

Barclays reiterates Overweight rating on Nvidia stock with a $275 price target after strong quarterly results and raised guidance.

Julianne Alice
ByJulianne Alice- Senior Editor
|
0

Barclays maintained its Overweight rating and $275 price target on Nvidia Corp. (NASDAQ:NVDA) following the company’s latest quarterly results. The chipmaker, with a market capitalization of $5.41 trillion, reported 65% revenue growth over the last twelve months to reach $215.94 billion.

The chipmaker reported a revenue beat and raised its guidance for the current period. Nvidia reiterated its projection of $1 trillion in cumulative revenue from Blackwell, Rubin, and networking products from 2025 through 2027, approximately $40 billion above consensus estimates for those periods.

The company increased its purchase commitments with suppliers to $119 billion from $95 billion. Nvidia also announced a significant dividend increase during the quarter. According to Bond.az data, the company has maintained dividend payments for 15 consecutive years, underscoring its commitment to shareholder returns.

Barclays noted several areas that may draw investor scrutiny, including a $20 billion CPU revenue figure, commentary on the market for the LPU product, an unexpected reorganization of business segments, and remarks about the company’s position at major hyperscale customers with custom silicon programs.

The firm’s Asia supply chain checks indicated a potential delay for Rubin shipments toward the end of the year, though Nvidia stated no change to its timeline with shipments beginning in the third quarter.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
842

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
730

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...